Literature DB >> 22025902

IFN-conditioned dendritic cells for the therapy of melanoma: what is missing?

Doru T Alexandrescu1, Thomas E Ichim, Neil H Riordan, Francesco M Marincola, Constantin A Dasanu.   

Abstract

Entities:  

Year:  2011        PMID： 22025902      PMCID： PMC3184394          DOI： 10.1097/CJI.0b013e31822b9ffc

Source DB:  PubMed          Journal:  J Immunother        ISSN： 1524-9557            Impact factor:   4.456


× No keyword cloud information.
  15 in total

Review 1.  Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance.

Authors:  F M Marincola; E M Jaffee; D J Hicklin; S Ferrone
Journal:  Adv Immunol       Date:  2000       Impact factor: 3.543

2.  IFN-α boosts epitope cross-presentation by dendritic cells via modulation of proteasome activity.

Authors:  Laura Lattanzi; Carmela Rozera; Diego Marescotti; Giuseppina D'Agostino; Laura Santodonato; Silvia Cellini; Filippo Belardelli; Riccardo Gavioli; Maria Ferrantini
Journal:  Immunobiology       Date:  2010-10-21       Impact factor: 3.144

3.  Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG.

Authors:  D Schadendorf; S Ugurel; B Schuler-Thurner; F O Nestle; A Enk; E-B Bröcker; S Grabbe; W Rittgen; L Edler; A Sucker; C Zimpfer-Rechner; T Berger; J Kamarashev; G Burg; H Jonuleit; A Tüttenberg; J C Becker; P Keikavoussi; E Kämpgen; G Schuler
Journal:  Ann Oncol       Date:  2006-01-17       Impact factor: 32.976

4.  Interferon-conditioned dendritic cells for melanoma immunotherapy.

Authors:  Arpád Farkas; Lajos Kemény
Journal:  J Immunother       Date:  2011-10       Impact factor: 4.456

5.  Improved survival with ipilimumab in patients with metastatic melanoma.

Authors:  F Stephen Hodi; Steven J O'Day; David F McDermott; Robert W Weber; Jeffrey A Sosman; John B Haanen; Rene Gonzalez; Caroline Robert; Dirk Schadendorf; Jessica C Hassel; Wallace Akerley; Alfons J M van den Eertwegh; Jose Lutzky; Paul Lorigan; Julia M Vaubel; Gerald P Linette; David Hogg; Christian H Ottensmeier; Celeste Lebbé; Christian Peschel; Ian Quirt; Joseph I Clark; Jedd D Wolchok; Jeffrey S Weber; Jason Tian; Michael J Yellin; Geoffrey M Nichol; Axel Hoos; Walter J Urba
Journal:  N Engl J Med       Date:  2010-06-05       Impact factor: 91.245

6.  Exosomes derived from interleukin-10-treated dendritic cells can inhibit trinitrobenzene sulfonic acid-induced rat colitis.

Authors:  Xiaojun Yang; Song Meng; Hong Jiang; Tao Chen; Wenxi Wu
Journal:  Scand J Gastroenterol       Date:  2010-10       Impact factor: 2.423

7.  Multicenter phase II study of matured dendritic cells pulsed with melanoma cell line lysates in patients with advanced melanoma.

Authors:  Antoni Ribas; Luis H Camacho; Sun Min Lee; Evan M Hersh; Charles K Brown; Jon M Richards; Maria Jovie Rodriguez; Victor G Prieto; John A Glaspy; Denise K Oseguera; Jackie Hernandez; Arturo Villanueva; Bartosz Chmielowski; Peggie Mitsky; Nadège Bercovici; Ernesto Wasserman; Didier Landais; Merrick I Ross
Journal:  J Transl Med       Date:  2010-09-27       Impact factor: 5.531

8.  Selective CD4+ lymphopenia in melanoma patients treated with temozolomide: a toxicity with therapeutic implications.

Authors:  Y B Su; Sejean Sohn; Susan E Krown; Philip O Livingston; Jedd D Wolchok; Carolyn Quinn; Linda Williams; Theresa Foster; Kent A Sepkowitz; Paul B Chapman
Journal:  J Clin Oncol       Date:  2004-01-15       Impact factor: 44.544

9.  Biochemotherapy of metastatic malignant melanoma. On down-regulation of CD28.

Authors:  Annika Håkansson; Leif Håkansson; Bertil Gustafsson; Lennart Krysander; Björn Rettrup; Dirk Ruiter; Monique R Bernsen
Journal:  Cancer Immunol Immunother       Date:  2002-08-27       Impact factor: 6.968

10.  Temozolomide followed by combined immunotherapy with GM-CSF, low-dose IL2 and IFN alpha in patients with metastatic melanoma.

Authors:  G C de Gast; D Batchelor; M J Kersten; F A Vyth-Dreese; J Sein; W F van de Kasteele; W J Nooijen; O E Nieweg; M A de Waal; W Boogerd
Journal:  Br J Cancer       Date:  2003-01-27       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.